<strike id="r533l"><i id="r533l"><del id="r533l"></del></i></strike>
<strike id="r533l"><dl id="r533l"></dl></strike>
<strike id="r533l"><dl id="r533l"></dl></strike>
<span id="r533l"></span>
<strike id="r533l"><video id="r533l"></video></strike><strike id="r533l"><dl id="r533l"></dl></strike><span id="r533l"><video id="r533l"></video></span>
<span id="r533l"><dl id="r533l"><ruby id="r533l"></ruby></dl></span>


Our unique ability to repeatedly and consistently translate science into medicine has led to a robust pipeline of clinical-stage medicines, all of which were discovered in our laboratories. Our investigational treatments target allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

Interact with the Regeneron Pipeline

Select Therapeutic Area(s):
Select Phase(s):
Select Collaborator(s):

Displaying item(s)

Clear Filters

Regeneron Pipeline: Phase 1 Medicines Regeneron Pipeline: Phase 1 Medicines
    SARS-CoV-2 Antibodies Treatment for hospitalized patients and non-hospitalized patients with COVID-19
    PD-1 Antibody Cancer
  • REGN3767
    LAG-3 Antibody Solid tumors, advanced hematologic malignancies
  • REGN1979
    CD20 X CD3 Antibody B-cell malignancies
  • REGN4018*
    MUC16 X CD3 Antibody Platinum-resistant ovarian cancer
  • REGN5458*
    BCMA X CD3 Antibody Multiple myeloma
  • REGN5459*
    BCMA X CD3 Antibody Multiple myeloma
  • REGN5678
    PSMA X CD28 Antibody Prostate cancer
  • REGN5093
    MET X MET Antibody MET-altered advanced non-small cell lung cancer (NSCLC)
  • REGN5713-5714-5715
    Bet v 1 Antibodies Birch Allergy
Regeneron Pipeline: Phase 2 Medicines Regeneron Pipeline: Phase 2 Medicines
    VEGF-Trap High-dose (8mg) for wet age-related macular degeneration (AMD)
    PD-1 Antibody Basal cell carcinoma (BCC), metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), neoadjuvant CSCC
  • REGN1979
    CD20 X CD3 Antibody B-cell non-Hodgkin lymphoma
    IL-6R Antibody Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis
    IL-4R Antibody Grass allergy, peanut allergy
  • REGN1908-1909
    Fel d 1 Antibodies Cat allergy
  • REGN3500*
    IL-33 Antibody Asthma, chronic obstructive pulmonary disease (COPD)
  • REGN5069
    GFRα3 Antibody Osteoarthritis pain of the knee
    Activin A Antibody Fibrodysplasia Ossificans Progressiva (FOP)
    ANGPTL-3 Antibody Refractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemia
    C5 Antibody Paroxysmal nocturnal hemoglobinuria, CD-55 deficient protein-losing enteropathy
  • REGN4461
    LEPR Antibody Generalized lipodystrophy
Regeneron Pipeline: Phase 3 Medicines Regeneron Pipeline: Phase 3 Medicines
    VEGF-Trap Retinopathy of prematurity (ROP)
    PD-1 Antibody non-small cell lung cancer (NSCLC), cervical cancer, adjuvant cutaneous squamous cell carcinoma (CSCC)
    PCSK9 Antibody Homozygous familial hypercholesterolemia (HoFH) in adults and pediatric patients, heterozygous familial hypercholesterolemia in pediatric patients
    ANGPTL-3 Antibody Homozygous familial hypercholesterolemia (HoFH)
    IL-4R Antibody Atopic dermatitis in pediatric patients 6 mo.–11 y.o., asthma in pediatric patients 6-11 y.o., eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, prurigo nodularis, chronic spontaneous urticaria
    IL-6R Antibody Hospitalized "critical" COVID-19 patients, polymyalgia rheumatica, giant cell arteritis
  • REGN-EB3
    Ebola Virus Antibodies Ebola virus infection
    NGF Antibody Osteoarthritis pain of the knee or hip

No results found, please adjust your filter selection and try again.

* In collaboration with Sanofi

? In collaboration with Teva and Mitsubishi Tanabe

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.